Maryland HB1375 mandates health insurance coverage for long-term antibiotic treatment of Lyme disease and related tick-borne illnesses.

Maryland HB1375 requires insurers, nonprofit health service plans, and health maintenance organizations to cover the full length of long-term antibiotic treatment for Lyme disease and related tick-borne illnesses, as prescribed by a licensed physician. The bill prohibits these entities from imposing quantitative limits on the treatment or denying coverage solely because the treatment is categorized as unproven, experimental, or investigational. The law applies to all policies, contracts, and health benefit plans issued, delivered, or renewed in the state on or after January 1, 2027.

Maryland HB1375 mandates health insurance coverage for long-term antibiotic treatment of Lyme disease and related tick-borne illnesses.

Maryland HB1375 requires insurers, nonprofit health service plans, and health maintenance organizations to cover the full length of long-term antibiotic treatment for Lyme disease and related tick-borne illnesses, as prescribed by a licensed physician. The bill prohibits these entities from imposing quantitative limits on the treatment or denying coverage solely because the treatment is categorized as unproven, experimental, or investigational. The law applies to all policies, contracts, and health benefit plans issued, delivered, or renewed in the state on or after January 1, 2027.